查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
CAR-T 细胞治疗市场：按药物类型、按适应症、按最终用户、按国家、按地区 - 行业分析、市场规模、市场份额、预测 2023-2030
市场调查报告书
商品编码
1304643

CAR-T 细胞治疗市场：按药物类型、按适应症、按最终用户、按国家、按地区 - 行业分析、市场规模、市场份额、预测 2023-2030

CAR T-cell therapy Market with COVID-19 Impact Analysis, By Drug Type, By Indication, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年CAR-T细胞治疗市场规模将达到23.084亿美元，2023年至2030年復合年增长率为21.8%

CAR-T 细胞治疗市场-市场动态：

癌症患病率上升预计将推动市场需求

癌症患病率的增加预计将主导 CAR-T 细胞治疗市场的增长。嵌合抗原受体 CAR-T 细胞疗法是癌症免疫细胞疗法的一个进步的新支柱。目前可用的 CAR-T 细胞疗法是针对每位患者定制的。据世界卫生组织 (WHO) 称，癌症是全球头号死亡原因，到 2020 年，癌症将导致约 1000 万人死亡，即每 6 人中就有 1 人死于癌症。仅在美国，目前就有 1,000 多名患者正在接受 CAR-T 细胞治疗，并且已经启动了几项研究，以观察对应答者的长期影响。新型生物疗法研究的进展以及生物製剂可用性和安全性的提高预计将为 CAR-T 细胞疗法市场提供增长机会。严重危及生命的毒性、适度的抗肿瘤活性、抗原逃逸、运输限制和肿瘤侵袭限制是限制市场增长的因素。

CAR-T 细胞治疗市场关键洞察：

  • 根据我们的研究分析师分享的分析，预计在预测期内（2023-2030年），全球纸袋包装市场的年復合增长率约为21.8%。
  • 由于人们对可持续增长的认识不断增强，纸袋包装行业预计将以惊人的速度增长
  • 在药物类型细分中，TisagenRecuCel 药物类型预计将在 2022 年占据最大的市场份额
  • 有迹象表明，淋巴瘤是 2022 年的主要类型。
  • 从最终用户来看，酒店业将成为 2022 年的主导类型。
  • 按地区划分，北美是2022年的主要收入来源。

CAR-T 细胞治疗市场细分分析：

全球 CAR-T 细胞治疗市场根据药物类型、适应症、最终用户和地区进行细分。

按药物类型划分，市场分为 Ciloleucel、Tisagenlecleucel、Axicabtagene、Autoleucel、Brexucabtagene 等。Tisagenlecleucel 药物类型在市场上占据主导地位。最近批准的产品包括 Tisagenleucel，这是一种 CAR T 疗法，被批准用于使用患者的自体 T 细胞治疗 B 细胞急性淋巴细胞白血病 (B-ALL)。随着 Tissagenre-Clucel 现在成为 B-ALL 的护理标准，能够准确监测患者的 CAR T 细胞在临床上势在必行。

市场按适应症分为六类：慢性淋巴细胞白血病（CLL）、多发性骨髓瘤（MM）、淋巴瘤、急性淋巴细胞白血病等。该疗法是一种高度专业化的治疗方法，通过基因改造患者自身的 T 细胞来攻击癌症。

市场按最终用户分为六类：医院和癌症治疗中心。酒店业是 2022 年的主导类型。拥有 CAR-T 细胞治疗项目的专业癌症中心和医院具备充分的条件来实施这种疗法。这些医院拥有基础设施、设施和经验丰富的医疗专业人员，可以提供安全有效的护理。

CAR-T细胞治疗市场-地理洞察：

从地理上看，该市场遍布北美、拉丁美洲、欧洲、亚太地区、中东和非洲。这些区域根据我们开展业务的国家/地区进一步细分。癌症负担的增加以及CAR-T细胞疗法研发的增加预计将推动北美CAR-T细胞疗法市场的增长。据美国癌症协会预测，2021年美国新增癌症病例和死亡人数预计将增至190万例，癌症死亡人数将达到60万人，预计为8570人。由于与嵌合抗原受体 CAR-T 细胞疗法相关的产品批准不断增加，欧洲和亚太地区预计将推动 CAR-T 细胞疗法市场的显着增长。

CAR-T细胞治疗市场-竞争格局：

公司正在大力投资研发，以加强细胞系开发技术、开发新产品并探索新的治疗应用。这些公司提供广泛的服务，包括合同研究、合同製造、临床试验服务以及为生物製药公司提供的其他支持服务。一家开发平台技术以提高 CAR-T 细胞疗法安全性的生物技术公司向 Alacrity 寻求全面的竞争格局研究，以更好地了解当前 CAR-T 细胞疗法领域。该公司希望了解正在开发的主要 CAR-T 细胞疗法的公司概况、该领域当前的挑战、其他公司采用的解决方案以及交易状态。这将作为业务战略和产品开发战略的指南，以最大限度地发挥自身技术的价值。

最近的发展

Johnson & Johnson旗下 Janssen Pharma 2023 年 5 月 2 日宣布已达成全球合作和许可，开发下一代嵌合抗原受体 CAR-T 细胞疗法，用于治疗 B 细胞恶性肿瘤与Cellular Biomedicine Group Inc. (CBMG ) 就製造和商业化达成协议。

调查的主要特点

本研究报告以2022年为基准年，提供了CAR-T细胞治疗市场的市场规模、复合年增长率（CAGR%）、估计和预测（2023-2030年）。

该研究报告为客户提供了对 CAR-T 细胞治疗市场最新发展的深入了解。

该研究报告阐明了不同细分市场/国家的潜在增长机会，并描述了 CAR-T 细胞治疗市场有吸引力的投资主张矩阵。

总体报告确定了 CAR-T 细胞治疗市场的新兴投资机会、现有企业面临的挑战以及持续增长动力。

研究范围详细讨论了 COVID-19 对 CAR-T 细胞疗法市场规模、预测、复合年增长率和市场动态的影响。它还涵盖了对新冠疫情后 CAR-T 细胞治疗市场的详细见解。

为了向本报告的用户提供对 CAR-T 细胞治疗市场的全面了解，我们还包括了 CAR-T 细胞治疗市场的竞争格局和关键创新者分析。

该研究涵盖了基于市场规模、增长率和吸引力对所有行业领域进行基准测试的增长前景映射分析。

提供主要市场进入者的详细公司简介，帮助您了解 CAR-T 细胞治疗市场运营公司的财务信息和战略举措。

此外，报告还揭示了市场主要进入者不仅在全球层面而且在区域层面的重大收购和兼併、联盟和合资企业、新产品推出、研发和区域扩张。

全球 CAR-T 细胞治疗市场报告主要面向该行业的各个利益相关者，如供应商、投资者、新进入者、分销商和财务分析师。

目录

第一章 CAR-T细胞治疗市场概况

  • 调查范围
  • 预计上市年限

第二章执行摘要

  • 市场细分
  • 竞争考虑

第三章 CAR-T细胞疗法主要市场趋势

  • CAR-T细胞治疗市场驱动因素
  • CAR-T细胞治疗市场製约因素
  • CAR-T细胞疗法的市场机会
  • CAR-T细胞治疗市场未来趋势

第四章 CAR-T细胞治疗行业概况

  • PEST分析
  • 波特五力分析
  • 绘製增长前景
  • 监管框架分析

第五章 CAR-T细胞治疗市场：COVID-19的影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后的影响分析

第六章 CAR-T细胞治疗市场格局

  • 2022 年 CAR-T 细胞疗法市场份额分析
  • 主要製造商的细分数据
    • 已成立公司分析
    • 启动分析

7. CAR-T细胞治疗市场——按药物类型

  • 概述
    • 按药品类型划分的细分市场份额分析
    • Axicabutagen/Siloleucel
    • Tisagen Reclusell
    • brexcabutagen autoleucel
    • 其他

8. CAR-T细胞治疗市场-按适应症分类

  • 概述
    • 按指标划分的细分市场份额分析
    • 淋巴瘤
    • 急性淋巴细胞白血病
    • 慢性淋巴细胞白血病（CLL）
    • 多发性骨髓瘤 (MM)
    • 其他

9. CAR-T细胞治疗市场-按最终用户划分

  • 概述
    • 按最终用户划分的细分市场份额分析
    • 医院
    • 癌症治疗中心

第10章CAR-T细胞治疗市场按地区

  • 介绍
  • 北美
    • 概述
    • 北美CAR-T细胞疗法领先製造商
    • 美国
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲领先的 CAR-T 细胞疗法製造商
    • 德国
    • 意大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 其他
  • 亚太地区 (APAC)
    • 概述
    • 亚太区领先的CAR-T细胞疗法製造商
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳大利亚
    • 泰国
    • 印度尼西亚
    • 菲律宾
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲 CAR-T 细胞疗法领先製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他
  • 中东和非洲
    • 概述
    • 中东和非洲领先的 CAR-T 细胞疗法製造商
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他

第十一章重点厂商分析-CAR-T细胞治疗行业

  • 比赛仪表板
  • 公司简介
    • Johnson & Johnson Services, Inc.
    • ALLOGENE THERAPEUTICS
    • Lonza
    • Aurora Biopharma
    • Cartesian Therapeutics, Inc.
    • Novartis
    • Bristol-Myers Squibb company
    • Gilead Sciences
    • Curocell Inc
    • JW Therapeutics

第十二章 分析师的全面看法

Product Code: ANV1382

REPORT HIGHLIGHT

CAR T-cell therapy Market size was valued at USD 2,308.4 million in 2022, expanding at a CAGR of 21.8% from 2023 to 2030.

Chimeric antigen receptor (CAR)-T cell therapy has been revolutionary as it has produced remarkably effective and durable clinical responses. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy. These therapies do not require aggressive chemotherapy, and unless there is an elevation in cytokines following infusion, patients receiving CAR T-cells do not typically require immunosuppression. The advantage of chimeric antigen receptor (CAR) T-cell therapy is that it is administered in a single infusion, requiring a shorter treatment time. Also, It Improves immunogenic memory, which provides continuous surveillance to treat local and distant metastatic lesions. The main benefit of CAR-T therapy is that it can be curative for people whose blood cancer has not responded to other types of treatments. While CAR-T therapy is often considered a last resort, it is often an effective one.

CAR T-cell therapy Market- Market Dynamics:

The increasing prevalence of cancer is expected to propel market demand

The increasing prevalence of cancer is expected to dominate the growth of the CAR T-cell therapy Market. Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. Currently, available CAR T-cell therapies are customized for each individual patient. According to World health organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In the United States alone, well over 1000 patients have now received CAR-T cells, and several studies have opened looking at the long-term effects in responders. Advancing research on novel biotherapies and increasing the supply and safety of biologics are the factors that are expected to provide growth opportunities for the CAR T-cell therapy market. The severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration are the factors which restrict the growth of market.

CAR T-cell Therapy Market- Key Insights:

  • As per the analysis shared by our research analyst, the global CAR T-cell therapy market is estimated to grow annually at a CAGR of around 21.8% over the forecast period (2023-2030)
  • Based on Drug Type segmentation, Tisagenlecleucel drug type was predicted to show maximum market share in the year 2022
  • Based on Indication segmentation, Lymphoma was the leading type in 2022
  • Based on End-User segmentation, Hospitals was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

CAR T-cell Therapy Market- Segmentation Analysis:

The Global CAR T-cell therapy Market is segmented on the basis of Drug Type, Indication, End User, and Region.

The market is divided into five categories based on Drug Type: Ciloleucel, Tisagenlecleucel, Axicabtagene, Autoleucel, Brexucabtagene, and Others. Tisagenlecleucel drug type dominates the market. One such recently licensed product has been Tisagenlecleucel, a CAR T therapy approved for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) using autologous T cells from the patient. Since Tisagenlecleucel is now a standard of care treatment for B-ALL, it is clinically essential to be able to accurately monitor these CAR T cells in patients.

The market is divided into six categories based on Indication: Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Lymphoma, Acute Lymphocytic Leukemia, and Others. dominates the market and is likely to maintain its dominance during the forecast period. It is a highly specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer.

The market is divided into six categories based on End -User: Hospitals and Cancer Treatment Centers. Hospitals are the leading type in 2022. Hospitals with specialized cancer centers or designated CAR T-cell therapy programs are equipped to handle the administration of this therapy. They have the infrastructure, facilities and experienced health professionals to provide safe and effective treatment.

CAR T-cell therapy Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The increasing burden of cancer and the rise in research and development to develop CAR T-cell therapy is expected to drive the growth of CAR T-cell therapy Market in north America. According to the American cancer society, number of new cancer cases and deaths in 2021 (In 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Europe and Asia Pacific are expected to propel significant growth in CAR T-cell therapy Market, due to the Growing Product Approvals Associated with Chimeric antigen receptor (CAR)-T cell therapy.

CAR T-cell therapy Market- Competitive Landscape:

Companies invest heavily in research and development to enhance their cell line development technologies, develop new products, and explore novel therapeutic applications. These players offer a wide range of services, including contract research, contract manufacturing, clinical trial services, and other support services for biopharmaceutical companies. A biotech company developing a platform technology to improve the safety of CAR T-cell therapies asked Alacrity to conduct a comprehensive competitive landscape to better understand the current CAR T-cell therapy space. The company wanted to understand the product profiles of top CAR T-cell therapies in development, current challenges in the field and solutions other companies are employing, as well as the deals landscape. This would help guide their business and product development strategy to maximize the value of their technology.

Recent Developments:

In May 2, 2023 -one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced nowadays that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

Key features of the study:

This proposed research study on CAR T-cell therapy market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year

The report provides the client the latest up-to-date and trending insights about the CAR T-cell therapy market.

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for CAR T-cell therapy market

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the CAR T-cell therapy market

Impact of COVID-19 on CAR T-cell therapy market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on CAR T-cell therapy market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the CAR T-cell therapy market, we have also included competitive landscape and key innovator analysis for the CAR T-cell therapy market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the CAR T-cell therapy market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

The global CAR T-cell therapy market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS

  • Johnson & Johnson Services, Inc.
  • ALLOGENE THERAPEUTICS
  • Lonza
  • Aurora Biopharma
  • Cartesian Therapeutics, Inc.
  • Novartis
  • Bristol-Myers Squibb company
  • Gilead Sciences
  • Curocell Inc
  • JW Therapeutics

GLOBAL CAR T-CELL THERAPY MARKET, BY DRUG TYPE

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION

  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma (MM)
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY END-USER

  • Hospitals
  • Cancer Treatment Centers

GLOBAL CAR T-CELL THERAPY MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. CAR T-Cell Therapy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CAR T-Cell Therapy Market Snippet by Drug Type
    • 2.1.2. CAR T-Cell Therapy Market Snippet by Indication
    • 2.1.3. CAR T-Cell Therapy Market Snippet by End User
    • 2.1.4. CAR T-Cell Therapy Market Snippet by Country
    • 2.1.5. CAR T-Cell Therapy Market Snippet by Region
  • 2.2. Competitive Insights

3. CAR T-Cell Therapy Key Market Trends

  • 3.1. CAR T-Cell Therapy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CAR T-Cell Therapy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CAR T-Cell Therapy Market Opportunities
  • 3.4. CAR T-Cell Therapy Market Future Trends

4. CAR T-Cell Therapy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CAR T-Cell Therapy Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. CAR T-Cell Therapy Market Landscape

  • 6.1. CAR T-Cell Therapy Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CAR T-Cell Therapy Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2022 & 2030 (%)
    • 7.1.2. Axicabtagene Ciloleucel
    • 7.1.3. Tisagenlecleucel
    • 7.1.4. Brexucabtagene Autoleucel
    • 7.1.5. Others

8. CAR T-Cell Therapy Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 8.1.2. Lymphoma
    • 8.1.3. Acute Lymphocytic Leukemia
    • 8.1.4. Chronic Lymphocytic Leukemia (CLL)
    • 8.1.5. Multiple Myeloma (MM)
    • 8.1.6. Others

9. CAR T-Cell Therapy Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Cancer Treatment Centers

10. CAR T-Cell Therapy Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. CAR T-Cell Therapy Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. CAR T-Cell Therapy Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. CAR T-Cell Therapy Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. CAR T-Cell Therapy Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. CAR T-Cell Therapy Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- CAR T-Cell Therapy Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Johnson & Johnson Services, Inc.
    • 11.2.2. ALLOGENE THERAPEUTICS
    • 11.2.3. Lonza
    • 11.2.4. Aurora Biopharma
    • 11.2.5. Cartesian Therapeutics, Inc.
    • 11.2.6. Novartis
    • 11.2.7. Bristol-Myers Squibb company
    • 11.2.8. Gilead Sciences
    • 11.2.9. Curocell Inc
    • 11.2.10. JW Therapeutics

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE CAR T-Cell Therapy Market: Drug Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Type
  • TABLE Global CAR T-Cell Therapy Market, by Drug Type 2018-2030 (USD Million)
  • TABLE CAR T-Cell Therapy Market: Indication Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global CAR T-Cell Therapy Market, by Indication 2018-2030 (USD Million)
  • TABLE CAR T-Cell Therapy Market: End User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global CAR T-Cell Therapy Market, by End User 2018-2030 (USD Million)
  • TABLE CAR T-Cell Therapy Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global CAR T-Cell Therapy Market, by Region 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)